BRPI0719995A2 - Composições e métodos para tratar distúrbios musculares & cardiovasculares - Google Patents

Composições e métodos para tratar distúrbios musculares & cardiovasculares

Info

Publication number
BRPI0719995A2
BRPI0719995A2 BRPI0719995-3A2A BRPI0719995A BRPI0719995A2 BR PI0719995 A2 BRPI0719995 A2 BR PI0719995A2 BR PI0719995 A BRPI0719995 A BR PI0719995A BR PI0719995 A2 BRPI0719995 A2 BR PI0719995A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
cardiovascular disorders
treat muscular
muscular
Prior art date
Application number
BRPI0719995-3A2A
Other languages
English (en)
Inventor
Iwan Beuvink
Jonathan Hall
Jan Weiler
Christian Schnell
Matthias Mueller
Martina Schinke-Braun
Fabrizio Serluca
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0719995A2 publication Critical patent/BRPI0719995A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
BRPI0719995-3A2A 2006-12-14 2007-12-13 Composições e métodos para tratar distúrbios musculares & cardiovasculares BRPI0719995A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86993706P 2006-12-14 2006-12-14
PCT/US2007/025535 WO2008076324A2 (en) 2006-12-14 2007-12-13 Compositions and methods to treat muscular & cardiovascular disorders

Publications (1)

Publication Number Publication Date
BRPI0719995A2 true BRPI0719995A2 (pt) 2014-03-18

Family

ID=39536897

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719995-3A2A BRPI0719995A2 (pt) 2006-12-14 2007-12-13 Composições e métodos para tratar distúrbios musculares & cardiovasculares

Country Status (11)

Country Link
US (3) US20100280094A1 (pt)
EP (1) EP2104733A2 (pt)
JP (3) JP2010512747A (pt)
KR (1) KR20090098818A (pt)
CN (2) CN101563458A (pt)
AU (1) AU2007334502B2 (pt)
BR (1) BRPI0719995A2 (pt)
CA (1) CA2672606A1 (pt)
EA (2) EA201101361A1 (pt)
MX (1) MX2009006310A (pt)
WO (1) WO2008076324A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2056882E (pt) 2006-08-01 2012-11-19 Univ Texas Identificação de um micro-rna que ativa a expressão da cadeia pesada de beta-miosina
NZ583025A (en) 2007-07-31 2012-06-29 Univ Texas Micro-rnas that control myosin expression and myofiber identity
WO2010091204A1 (en) 2009-02-04 2010-08-12 Board Of Regents, The University Of Texas System Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease
JP5757885B2 (ja) 2009-03-12 2015-08-05 ブランディーズ・ユニバーシティ Ｐｃｒ用の試薬および方法
BR112013012319A2 (pt) 2010-12-15 2019-09-24 Miragen Therapeutics inibidores de micro rna compreendendo nucleotídeos bloqueados
JP6177243B2 (ja) 2011-10-06 2017-08-09 ミラゲン セラピューティクス， インコーポレイテッド マイクロｒｎａの調節による全身エネルギーホメオスタシスの制御
WO2013192576A2 (en) 2012-06-21 2013-12-27 Miragen Therapeutics Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CA2888486A1 (en) * 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
US9637738B2 (en) * 2013-04-10 2017-05-02 Reveragen Biopharma, Inc. Methods and agents to increase therapeutic dystrophin expression in muscle
SG11201602597YA (en) 2013-10-11 2016-05-30 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
MX2017001674A (es) * 2014-08-04 2017-08-10 Miragen Therapeutics Inc Inhibidores de myh7b y usos de los mismos.
SG10201906716QA (en) 2015-01-20 2019-08-27 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
PL3283080T3 (pl) 2015-04-16 2020-07-27 Ionis Pharmaceuticals, Inc. Kompozycja do modulowania ekspresji c9orf72
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
CN106148519A (zh) * 2016-07-05 2016-11-23 无锡市第二人民医院 一种microRNA‑499的快速检测方法
CN111630166B (zh) * 2017-08-10 2024-04-19 希望之城 条件性-siRNA及其在治疗心肌肥大中的用途
KR102281710B1 (ko) 2021-02-19 2021-07-28 조기정 에어튜브를 이용한 선박 안전장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
IL113519A (en) * 1990-08-03 1997-11-20 Sterling Winthrop Inc Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage, their preparation and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
JP3516167B2 (ja) * 1992-12-08 2004-04-05 ローム株式会社 タンタルコンデンサチップの製造方法
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
TR200401292T3 (tr) * 2000-12-01 2004-07-21 Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften RNAÁgirişimineÁyolÁaçanÁküçükÁRNAÁmolekülleri
AU2004257373B2 (en) * 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
WO2005021800A2 (en) * 2003-08-22 2005-03-10 Sirna Therapeutics, Inc. Detection and quantitation of nucleic acid molecules in biological samples
EP1784501B1 (en) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
EP1877557A2 (en) * 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Micro-rna's that regulate muscle cells
US20070092882A1 (en) * 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
EP1984497A2 (en) * 2006-01-10 2008-10-29 Koninklijke Nederlandse Akademie van Wetenschappen Nucleic acid molecules and collections thereof, their application and identification
PT2056882E (pt) * 2006-08-01 2012-11-19 Univ Texas Identificação de um micro-rna que ativa a expressão da cadeia pesada de beta-miosina
NZ583025A (en) * 2007-07-31 2012-06-29 Univ Texas Micro-rnas that control myosin expression and myofiber identity

Also Published As

Publication number Publication date
US20120114744A1 (en) 2012-05-10
CN102604951A (zh) 2012-07-25
JP2010512747A (ja) 2010-04-30
CN101563458A (zh) 2009-10-21
JP2012019789A (ja) 2012-02-02
US20100280094A1 (en) 2010-11-04
AU2007334502B2 (en) 2011-12-15
WO2008076324A3 (en) 2009-04-09
CA2672606A1 (en) 2008-06-26
EP2104733A2 (en) 2009-09-30
EA201101361A1 (ru) 2012-11-30
MX2009006310A (es) 2009-07-22
EA200900782A1 (ru) 2009-12-30
WO2008076324A2 (en) 2008-06-26
JP2012131812A (ja) 2012-07-12
US20120041052A1 (en) 2012-02-16
AU2007334502A1 (en) 2008-06-26
KR20090098818A (ko) 2009-09-17

Similar Documents

Publication Publication Date Title
BRPI0719995A2 (pt) Composições e métodos para tratar distúrbios musculares & cardiovasculares
HK1219306A1 (zh) 用於睡眠障礙和其他疾病的方法和組合物
SMT201500176B (it) Composizioni e metodi per inibire l'espressione ditranstiretina
EP2120580A4 (en) COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
BRPI1014522A2 (pt) composicoes e metodos para aumentar o crescimento muscular
BRPI0815407A2 (pt) Composições e métodos para controlar nematódeos
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
SG2014014153A (en) Preventing and/or treatingmetabolic disorders by modulatingthe amount of enterobacteria
ZA201001107B (en) Citrus oil compositions and methods of use
EP2209375A4 (en) PARP HEMMER, COMPOSITIONS AND METHOD FOR THEIR USE
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
NO20090079L (no) Arylsulfonamider med analgesisk virkning
DK3135672T3 (da) Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
IL194189A0 (en) Combination treatment of metabolic disorders
SI2300614T1 (sl) Metode in sestavki za zdravljenje mitohondrijskih motenj
EP2309858A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
BRPI0722183A2 (pt) Composições farmacêuticas para tratar depressão e ansiedade
HK1145995A1 (en) Herbal compositions and methods for treating hepatic disorders

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.